"Reiterate BUY, $6 target on continued Nuedexta growth, robust sales estimates. Nuedexta is AVNR’s drug for pseudobulbar
affect, emotional lability seen in stroke, traumatic brain injury, Alzheimer’s and other neurodegenerative disorders. Launch
has been steady, and we see new positive trends. Our peak annual sales estimates are $350M US, $300M EU. Our $6 target is
based on a sum-of- the-parts analysis."
"AVP-786 (deuterated dextromethorphan) formulation shows similar PK, safety to Nuedexta with substantially less
"AVNR will cut size of PRIME study in half as the company shifts development focus to AVP-786"